Almac has expanded its commercial business unit with the opening of a new commercial packaging facility in the U.S. and enhanced processing capabilities at its headquarters in Craigavon, UK. In Feb 2013, following FDA approval, Almac opened its U.S. commercial packaging facility providing services for both solid oral dosage forms and biopharmaceutical products. The company also expanded commercial manufacturing and packaging at its UK facilities, adding significant capacity for commercial fluid bed drying and high-speed encapsulation.   
 
Additionally, in response to growing demand from several Japanese partners for enhanced flexibility related to larger blister sizes and requirement for non-permeability and environmental protection, the company has also made investments in blistering technology with product humidity control. The most recent commercial expansion completed at the UK site was a client-led investment in dedicated facilities, doubling sachet output to 250 million sachets per year.
 
David Downey, vice president, commercial operations said, “Almac continues to grow in partnership with our clients and is developing a strong reputation for the delivery of complex, time sensitive capital projects in support of growing, innovative products. This level of commercial investment demonstrates our commitment to building long term, strategic relationships.”